This clinical trial is focused on studying a lung condition called non-cystic fibrosis bronchiectasis. This condition involves damage to the airways, leading to symptoms like a persistent cough and frequent lung infections. The study will test a treatment called itepekimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body. Itepekimab is designed to target and block a protein called interleukin-33, which is involved in inflammation.
The purpose of the study is to evaluate how effective itepekimab is compared to a placebo in reducing lung flare-ups, known as pulmonary exacerbations, in people with non-cystic fibrosis bronchiectasis. Participants in the study will receive either itepekimab or a placebo through an injection under the skin. The study will monitor participants over a period to see how often these lung flare-ups occur and to assess the safety and tolerability of the treatment.
Throughout the study, various aspects will be observed, such as the time it takes for the first lung flare-up to occur, the number of participants who remain free from these flare-ups, and any changes in lung function. The study will also look at the quality of life related to respiratory symptoms and any side effects that may arise from the treatment. The goal is to gather information that could help improve the management of non-cystic fibrosis bronchiectasis in the future.
Czechia 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
The Netherlands 